Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
NCT00951496Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2009
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, cisplatin and Paclitaxel Micelles for Injection in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival up to 10 years. Started Aug 2009; status: completed.
02
Drugs
carboplatincisplatinPaclitaxel Micelles for Injection
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00951496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951496.